COMMUNIQUÉS West-GlobeNewswire

Kailera Therapeutics to Participate in Upcoming November Investor Conferences
05/11/2025
WALTHAM, Mass. and SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing a differentiated, late-stage portfolio of next-generation [...]
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results
05/11/2025
Announced positive results from two pivotal Phase 3 Essential3 studies of ulixacaltamide HCl in essential tremor (ET); Pre-NDA meeting with FDA scheduled for Q4 2025 Plans to accelerate the development of relutrigine in [...]
Beyond Air® Secures Up to $32 Million to Accelerate Growth
05/11/2025
Enters agreements for a $12 million promissory note and a $20 million equity line of credit with Streeterville Capital Proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of [...]
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
05/11/2025
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet [...]
23andMe Research Institute Appoints Kael Reicin as Chief Financial Officer
05/11/2025
Reicin Brings Financial and Operational Nonprofit Expertise to the Newly Formed Nonprofit Organization PALO ALTO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- 23andMe Research Institute, a nonprofit medical research [...]
Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
05/11/2025
-- Milestone advances two-part study evaluating novel, locally administered gene therapy designed to increase anti-inflammatory IL-1Ra production in the knee joint -- BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- [...]
LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
05/11/2025
VIZZ TM (aceclidine ophthalmic solution) 1.44% received FDA approval for the treatment of presbyopia Commercial product launch initiated in October 2025 with broad product availability in mid-Q4 2025 Over 2,500 ECPs [...]
MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
05/11/2025
Conference call today at 9:00 am ET Q3 2025 revenues of $82.1M, +17% v. Q3 2024 YTD 2025 revenues of $237.0M, +14% v. YTD 2024 Completed acquisition of scPharmaceuticals on October 7, accelerating MannKind’s revenue [...]
Telix to Participate in UBS and Jefferies Global Healthcare Conferences
05/11/2025
MELBOURNE, Australia and INDIANAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will participate in the upcoming UBS Global Healthcare Conference in Palm Beach, FL [...]
Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies
05/11/2025
DSAP is a premalignant, progressive disease characterized by numerous expanding lesions which significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.S. [...]
Immuron IMM-529 IND approved by FDA
05/11/2025
Key Points Immuron receives U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) application and clinical study may proceed FDA assigned an IND number (032095) for the IMM-529 [...]
RadNet Expands Comprehensive Remote Scanning Offering with Acquisition of Alpha RT’s Assets
05/11/2025
RadNet subsidiary DeepHealth to commercialize a robust end-to-end remote-imaging offering featuring both TechLive™ remote scanning technology and Alpha RT’s MRI staffing services and training programs LOS ANGELES, Nov. [...]
Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
05/11/2025
Marks Aclarion’s first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgery Experiencing strong commercial traction in UK as first market [...]
Maple acquires Beyond ADHD to expand responsible ADHD and mental health care across Canada
05/11/2025
Acquisition strengthens access to clinically led virtual ADHD and mental health programs nationwide TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Maple, Canada’s leading virtual care company, today announced the [...]
Oculis to Participate in Upcoming November Investor Conferences
05/11/2025
ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical [...]
Oculis to Participate in Upcoming November Investor Conferences
05/11/2025
ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical [...]
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
05/11/2025
COPENHAGEN, Denmark, November 5, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4.92% [...]
TME Pharma advances its new investment strategy and signs LOI with German resources company
05/11/2025
TME Pharma advances its new investment strategy and signs LOI with German resources company A further step toward investment diversification into potential cash-flow–generating assets A potential strategic investment in [...]
TME PHARMA POURSUIT SA NOUVELLE STRATÉGIE D'INVESTISSEMENT ET SIGNE UNE LETTRE D'INTENTION AVEC UNE SOCIÉTÉ ALLEMANDE SPÉCIALISÉE DANS LES RESSOURCES NATURELLES
05/11/2025
TME PHARMA POURSUIT SA NOUVELLE STRATÉGIE D'INVESTISSEMENT ET SIGNE UNE LETTRE D'INTENTION AVEC UNE SOCIÉTÉ ALLEMANDE SPÉCIALISÉE DANS LES RESSOURCES NATURELLES Nouvelle étape vers la diversification des investissements [...]

Pages